Literature DB >> 22136312

Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity.

Romeo Romagnoli1, Pier Giovanni Baraldi, Maria Kimatrai Salvador, Delia Preti, Mojgan Aghazadeh Tabrizi, Andrea Brancale, Xian-Hua Fu, Jun Li, Su-Zhan Zhang, Ernest Hamel, Roberta Bortolozzi, Giuseppe Basso, Giampietro Viola.   

Abstract

Tubulin, the major structural component of microtubules, is a target for the development of anticancer agents. Two series of 1,5-diaryl substituted 1,2,3,4-tetrazoles were concisely synthesized, using a palladium-catalyzed cross-coupling reaction, and identified as potent antiproliferative agents and novel tubulin polymerization inhibitors that act at the colchicine site. SAR analysis indicated that compounds with a 4-ethoxyphenyl group at the N-1 or C-5 position of the 1,2,3,4-tetrazole ring exhibited maximal activity. Several of these compounds also had potent activity in inhibiting the growth of multidrug resistant cells overexpressing P-glycoprotein. Active compounds induced apoptosis through the mitochondrial pathway with activation of caspase-9 and caspase-3. Furthermore, compound 4l significantly reduced in vivo the growth of the HT-29 xenograft in a nude mouse model, suggesting that 4l is a promising new antimitotic agent with clinical potential.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136312      PMCID: PMC3266058          DOI: 10.1021/jm2013979

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  50 in total

1.  Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Olga Cruz-Lopez; Carlota Lopez Cara; Maria Dora Carrion; Andrea Brancale; Ernest Hamel; Longchuan Chen; Roberta Bortolozzi; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

Review 2.  Cell-cycle control in the face of damage--a matter of life or death.

Authors:  Paul R Clarke; Lindsey A Allan
Journal:  Trends Cell Biol       Date:  2009-01-23       Impact factor: 20.808

3.  Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles.

Authors:  Katiuscia Bonezzi; Giulia Taraboletti; Patrizia Borsotti; Fabio Bellina; Renzo Rossi; Raffaella Giavazzi
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

Review 4.  Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.

Authors:  Chryso Kanthou; Gillian M Tozer
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

5.  Direct C-H arylation and alkenylation of 1-substituted tetrazoles: phosphine as stabilizing factor.

Authors:  Marcel Spulák; Richard Lubojacký; Petr Senel; Jirí Kunes; Milan Pour
Journal:  J Org Chem       Date:  2010-01-01       Impact factor: 4.354

6.  4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.

Authors:  Rainer Schobert; Bernhard Biersack; Andrea Dietrich; Katharina Effenberger; Sebastian Knauer; Thomas Mueller
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

Review 7.  In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.

Authors:  Hiroaki Kiyokawa; Dipankar Ray
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

Review 8.  Tubulin-interactive natural products as anticancer agents.

Authors:  David G I Kingston
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

Review 9.  Microtubule dynamics as a target in oncology.

Authors:  April L Risinger; Francis J Giles; Susan L Mooberry
Journal:  Cancer Treat Rev       Date:  2008-12-30       Impact factor: 12.111

10.  1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin.

Authors:  Kristin Odlo; Jean Hentzen; Jérémie Fournier dit Chabert; Sylvie Ducki; Osman A B S M Gani; Ingebrigt Sylte; Martina Skrede; Vivi Ann Flørenes; Trond Vidar Hansen
Journal:  Bioorg Med Chem       Date:  2008-03-23       Impact factor: 3.641

View more
  21 in total

1.  Synthesis and anti-breast cancer activity of novel indibulin related diarylpyrrole derivatives.

Authors:  Ebrahim Saeedian Moghadam; Ernest Hamel; Zahra Shahsavari; Mohsen Amini
Journal:  Daru       Date:  2019-03-20       Impact factor: 3.117

2.  Molecular modeling study, synthesis and biological evaluation of combretastatin A-4 analogues as anticancer agents and tubulin inhibitors.

Authors:  Yang Ping Quan; Li Ping Cheng; Tian Chi Wang; Wan Pang; Fan Hong Wu; Jin Wen Huang
Journal:  Medchemcomm       Date:  2017-12-06       Impact factor: 3.597

3.  Correlation of hydrogen-bonding propensity and anticancer profile of tetrazole-tethered combretastatin analogues.

Authors:  Ganesh S Jedhe; Debasish Paul; Rajesh G Gonnade; Manas K Santra; Ernest Hamel; Tam Luong Nguyen; Gangadhar J Sanjayan
Journal:  Bioorg Med Chem Lett       Date:  2013-06-12       Impact factor: 2.823

4.  Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Filippo Prencipe; Valerio Bertolasi; Michela Cancellieri; Andrea Brancale; Ernest Hamel; Ignazio Castagliuolo; Francesca Consolaro; Elena Porcù; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2014-07-28       Impact factor: 7.446

5.  Exploring natural product chemistry and biology with multicomponent reactions. 5. Discovery of a novel tubulin-targeting scaffold derived from the rigidin family of marine alkaloids.

Authors:  Liliya V Frolova; Igor V Magedov; Anntherese E Romero; Menuka Karki; Isaiah Otero; Kathryn Hayden; Nikolai M Evdokimov; Laetitia Moreno Y Banuls; Shiva K Rastogi; W Ross Smith; Shi-Long Lu; Robert Kiss; Charles B Shuster; Ernest Hamel; Tania Betancourt; Snezna Rogelj; Alexander Kornienko
Journal:  J Med Chem       Date:  2013-08-23       Impact factor: 7.446

6.  Design and synthesis of 6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-one derivatives as novel anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase.

Authors:  Yi-Fong Chen; Yi-Chien Lin; Po-Kai Huang; Hsu-Chin Chan; Sheng-Chu Kuo; Kuo-Hsiung Lee; Li-Jiau Huang
Journal:  Bioorg Med Chem       Date:  2013-06-26       Impact factor: 3.641

7.  Selective anticancer activities of ruthenium(II)-tetrazole complexes and their mechanistic insights.

Authors:  Chanchal Sonkar; Novina Malviya; Nilima Sinha; Attreyee Mukherjee; Srimanta Pakhira; Suman Mukhopadhyay
Journal:  Biometals       Date:  2021-04-26       Impact factor: 2.949

8.  New (3-(1H-benzo[d]imidazol-2-yl))/(3-(3H-imidazo[4,5-b]pyridin-2-yl))-(1H-indol-5-yl)(3,4,5-trimethoxyphenyl)methanone conjugates as tubulin polymerization inhibitors.

Authors:  Kishore Mullagiri; V Lakshma Nayak; Satish Sunkari; Geeta Sai Mani; Sravanthi Devi Guggilapu; Burri Nagaraju; Abdullah Alarifi; Ahmed Kamal
Journal:  Medchemcomm       Date:  2017-12-12       Impact factor: 3.597

9.  Synthesis, Spectral Analysis, In Vitro Microbiological Evaluation, and Molecular Docking Studies of Some Novel 1-(1-Aryl-1H-tetrazol-5-yl)-2-(piperidin-1-yl)ethanone Derivatives.

Authors:  Thangasamy Elavarasan; Durairaj Peter Bhakiaraj; Mannathusamy Gopalakrishnan
Journal:  ISRN Org Chem       Date:  2014-05-06

10.  Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1H-Imidazole.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Filippo Prencipe; Paola Oliva; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Luisa Carlota Lopez-Cara; Salvatore Ferla; Andrea Brancale; Ernest Hamel; Roberto Ronca; Roberta Bortolozzi; Elena Mariotto; Giuseppe Basso; Giampietro Viola
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.